Rosa & Co. is pleased to announce it is offering DueDiligenceMD in addition to the ForecastMD™ Research Platform. For organizations that are evaluating assets for in-licensing, partnering, or acquisition, DueDiligenceMD quantifies and explains the expected physician demand for the asset, based on primary market research and an Excel®-based Revenue Model. DueDiligenceMD projects are typically completed within two weeks.Rosa & Co. is also enhancing our PhysioPD® Research with the use of Artificial Intelligence/ Machine Learning (AI/ML) techniques. PhysioPD Research provides biological context, facilitates insight into dynamics and causality, and supports hypothesis generation. Adding AI/ML techniques to PhysioPD Research speeds the identification of networks from data, supports empirical model and Virtual Patient creation, and enriches the insights extracted from simulation results.
See the press release at https://www.einnews.com/pr_news/590758247/rosa-announces-new-duediligencemd-pharma-asset-research-service-and-ai-ml-capabilities-for-physiopd